Agilent Technologies Inc. (NYSE: A) today announced the release of the Altura Ultra Inert HPLC Columns, a new range of high‑performance liquid chromatography (HPLC) columns designed for biotherapeutic applications such as peptide GLP‑1 and oligonucleotide development and quality control.
The Altura columns feature proprietary Ultra Inert technology that delivers up to twice the sensitivity and three times the signal‑to‑noise ratio compared with competitor columns, and when paired with the Agilent 1290 Infinity III Bio LC system can achieve up to 30× higher peak area. The improved conditioning, peak shape, and sensitivity are intended to help biopharma labs meet increasingly rigorous regulatory expectations and accelerate discovery of complex therapeutics.
By expanding its inert flow‑path portfolio, Agilent reinforces its strategy to provide innovative solutions that support high‑quality therapeutic development. The launch positions the company to capture a larger share of the growing biotherapeutics market and enhances its competitive edge in analytical performance for demanding applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.